Redeye comments on Sprint Bioscience’s Q4 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project H1 2023e after some setbacks in recent months. We tweak our estimates and valuation.
ANNONS
Redeye comments on Sprint Bioscience’s Q4 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project H1 2023e after some setbacks in recent months. We tweak our estimates and valuation.